Christopher Micetich is the founder and CEO of Edmonton-based Fedora Pharmaceuticals, which announced a major three-way global licensing deal Tuesday to develop and market a new compound to help antibiotics retain their effectiveness against drug-resistant infections.

Source: www.edmontonjournal.com

Advertisements